MedPath

The effect Dehydroepiandrosterone (DHEA) supplementation on IVF outcome

Phase 2
Conditions
Female infertility.
Female infertility
Registration Number
IRCT20160523028008N14
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
80
Inclusion Criteria

Candidates for IVF over 35 years
Body mass index between 18 and 25 (kg/m^2)
FSH hormone levels less than 10 IU /

Exclusion Criteria

Systemic diseases such as diabetes, thyroid diseases
History of ovarian surgery
History of receiving DHEA

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical pregnancy rate. Timepoint: Fourth week after intervention. Method of measurement: Based on Beta-HCG and ultrasound confirmation.;Chemical pregnancy rate. Timepoint: The second week after the intervention. Method of measurement: Based on Beta-HCG a confirmation.;Miscarriage rates. Timepoint: Before 6 and 20 weeks after the intervention. Method of measurement: File.;Endometrial thickness before embryo transfer. Timepoint: Before embryo transfer. Method of measurement: Using ultrasound.;Duration of stimulation. Timepoint: Time required for follicle growth. Method of measurement: Using ultrasound.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath